Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines
暂无分享,去创建一个
Jaakko Astola | Sampsa Hautaniemi | Reija Autio | Päivikki Kauraniemi | Anne Kallioniemi | Outi Monni | J. Astola | O. Monni | P. Kauraniemi | S. Hautaniemi | A. Elkahloun | A. Kallioniemi | R. Autio | Abdel Elkahloun
[1] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[2] W. Cleveland. Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .
[3] S. Safe,et al. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. , 2002, Biochemical and biophysical research communications.
[4] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[5] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Astola,et al. A strategy for identifying class-separating genes in drug-treatment microarray data , 2003 .
[7] B. Burg,et al. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells , 1989, Molecular and Cellular Endocrinology.
[8] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[9] L. Ashman,et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.
[10] J. Fletcher,et al. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.
[11] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[14] Michael L. Bittner,et al. Microarrays: Optical Technologies and Informatics , 2001 .
[15] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[16] Terence P. Speed,et al. Normalization for cDNA microarry data , 2001, SPIE BiOS.
[17] 김삼묘,et al. “Bioinformatics” 특집을 내면서 , 2000 .
[18] Michael L. Bittner,et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] Esa Alhoniemi,et al. SOM Toolbox for Matlab 5 , 2000 .
[20] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Teuvo Kohonen,et al. Self-Organizing Maps , 2010 .
[22] Jaakko Astola,et al. Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps , 2003, Machine Learning.